Citadel Advisors Portfolio holdings
Citadel Advisors, founded in 1990 by Kenneth C. Griffin as Citadel LLC and headquartered in Chicago, Illinois, is one of the world’s most prominent hedge funds, managing tens of billions in assets through sophisticated quantitative trading strategies. The firm excels in market-making and high-frequency trading across asset classes like equities, fixed income, options, and commodities, leveraging cutting-edge technology and data analysis to generate returns. Citadel operates two main arms: its hedge fund business, which serves institutional and high-net-worth investors, and Citadel Securities, a leading market maker that facilitates a significant portion of U.S. equity and options trades. Known for its secretive, high-performance culture, Citadel has grown into a financial titan under Griffin’s leadership, influencing global markets with its scale and innovation.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$555M |
| 2 |
Citigroup
C
|
+$407M |
| 3 |
Medtronic
MDT
|
+$401M |
| 4 |
Chipotle Mexican Grill
CMG
|
+$392M |
| 5 |
Gilead Sciences
GILD
|
+$362M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Invesco QQQ Trust
QQQ
|
+$1.43B |
| 2 |
Amazon
AMZN
|
+$1.32B |
| 3 |
Apple
AAPL
|
+$1.1B |
| 4 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$995M |
| 5 |
Bank of America
BAC
|
+$726M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 83.47% |
| 2 | Technology | 3.02% |
| 3 | Healthcare | 2.92% |
| 4 | Consumer Discretionary | 2.17% |
| 5 | Financials | 2.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
11651
PUT
Dana Inc
DAN
$3.02B
| $59.1K | ﹤0.01% |
5,600
-11,600
| -67% | -$128K |
2018 Q1
26 quarters
|
|
|
CLLS
11652
Cellectis
CLLS
$135M
| $59.1K | ﹤0.01% |
27,624
+925
| +3% | +$2.01K |
2024 Q2
1 quarter
|
|
11653
Oric Pharmaceuticals
ORIC
$1.24B
| $59.1K | ﹤0.01% |
+5,767
| New | +$57K |
2024 Q3
0 quarters
|
|
|
LILM
11654
PUT
DELISTED
Lilium N.V. Class A Ordinary Shares
LILM
| $59.1K | ﹤0.01% |
76,300
+39,200
| +106% | +$31.6K |
2021 Q3
12 quarters
|
|
|
PARAA
11655
PUT
DELISTED
Paramount Global Class A
PARAA
| $59K | ﹤0.01% |
2,700
+100
| +4% | +$2.21K |
2024 Q2
1 quarter
|
|
|
BCAB
11656
PUT
DELISTED
BIOATLA INC
BCAB
| $59K | ﹤0.01% |
670
+522
| +353% | +$43.8K |
2022 Q2
9 quarters
|
|
11657
CALL
Stellus Capital Investment Corp
SCM
$203M
| $58.9K | ﹤0.01% |
4,300
-5,000
| -54% | -$69.3K |
2021 Q2
13 quarters
|
|
|
VSTA
11658
DELISTED
Vasta Platform
VSTA
| $58.8K | ﹤0.01% |
22,354
+9,550
| +75% | +$26.6K |
2024 Q1
2 quarters
|
|
|
DADA
11659
CALL
DELISTED
Dada Nexus
DADA
| $58.7K | ﹤0.01% |
30,900
+14,200
| +85% | +$18.6K |
2021 Q1
14 quarters
|
|
11660
CALL
W&T Offshore
WTI
$539M
| $58.7K | ﹤0.01% |
27,300
+3,000
| +12% | +$6.67K |
2019 Q4
19 quarters
|
|
11661
GEE Group
JOB
$24.1M
| $58.6K | ﹤0.01% |
224,882
+72,063
| +47% | +$20.3K |
2023 Q1
6 quarters
|
|
|
GAN
11662
DELISTED
GAN Ltd
GAN
| $58.6K | ﹤0.01% |
+33,086
| New | +$54.5K |
2024 Q3
0 quarters
|
|
11663
CALL
Certara
CERT
$1.37B
| $58.5K | ﹤0.01% |
5,000
-3,000
| -38% | -$39.6K |
2022 Q1
10 quarters
|
|
11664
CALL
Telefônica Brasil
VIV
$20.3B
| $58.5K | ﹤0.01% |
+5,700
| New | +$52.7K |
2024 Q3
0 quarters
|
|
11665
VOC Energy
VOC
$58.1M
| $58.5K | ﹤0.01% |
11,866
-22,995
| -66% | -$114K |
2023 Q3
4 quarters
|
|
|
ATAI
11666
PUT
DELISTED
AtaiBeckley Inc
ATAI
| $58.3K | ﹤0.01% |
50,300
-54,300
| -52% | -$72.4K |
2021 Q3
12 quarters
|
|
11667
Medifast
MED
$128M
| $58.3K | ﹤0.01% |
3,046
-86,360
| -97% | -$1.66M |
2017 Q1
30 quarters
|
|
11668
PUT
Mineralys Therapeutics
MLYS
$1.95B
| $58.1K | ﹤0.01% |
4,800
+3,200
| +200% | +$38.7K |
2024 Q1
2 quarters
|
|
11669
Rani Therapeutics
RANI
$93.7M
| $58.1K | ﹤0.01% |
26,904
+12,139
| +82% | +$34.8K |
2024 Q1
2 quarters
|
|
11670
CALL
AMERISAFE
AMSF
$449M
| $58K | ﹤0.01% |
1,200
-2,100
| -64% | -$99.9K |
2024 Q1
2 quarters
|
|
|
JOYY
11671
CALL
JOYY Inc
JOYY
$3.98B
| $58K | ﹤0.01% |
1,600
-100
| -6% | -$3.44K |
2016 Q2
33 quarters
|
|
|
UBX
11672
CALL
DELISTED
Unity Biotechnology
UBX
| $57.9K | ﹤0.01% |
39,400
+25,900
| +192% | +$38K |
2021 Q2
13 quarters
|
|
11673
CALL
Duluth Holdings
DLTH
$152M
| $57.9K | ﹤0.01% |
15,400
+12,700
| +470% | +$46.4K |
2019 Q2
21 quarters
|
|
11674
CALL
Ultralife
ULBI
$106M
| $57.9K | ﹤0.01% |
6,400
+3,600
| +129% | +$37.1K |
2023 Q3
4 quarters
|
|
|
EVRI
11675
CALL
DELISTED
Everi Holdings
EVRI
| $57.8K | ﹤0.01% |
4,400
+4,000
| +1,000% | +$47.1K |
2020 Q1
18 quarters
|
|
Similar funds
Citadel Advisors's Q3 2024 Portfolio in Review
As of Q3 2024, Citadel Advisors held 15,731 positions worth $518B, up 4.9% from $494B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Citadel Advisors's Q3 2024 filing shows 1,612 new, 6,434 increased, 5,866 reduced and 1,610 closed positions. Its largest new stake was iShares 7-10 Year Treasury Bond ETF: 2,002,737 shares worth $197M. The largest sale was Invesco QQQ Trust, an estimated $1.43B.
By sector, the portfolio is most concentrated in Miscellaneous at 83% of assets, up from 82% a quarter earlier, followed by Technology and Healthcare.
- Citadel Advisors's largest Q3 2024 buy was iShares 7-10 Year Treasury Bond ETF: 2,002,737 shares worth $197M.
- Citadel Advisors added most to NVIDIA in Q3 2024, an estimated $555M increase.
- Citadel Advisors's biggest Q3 2024 reduction was Invesco QQQ Trust, cutting an estimated $1.43B.
- Citadel Advisors fully exited Domino's in Q3 2024, selling an estimated $186M.
- Citadel Advisors's ten largest holdings make up 30% of its $518B portfolio in Q3 2024.
- Citadel Advisors opened 1,612 new positions and closed 1,610 in Q3 2024.
- Citadel Advisors's portfolio value rose 4.9% quarter-over-quarter to $518B.
Based on Citadel Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.